Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
NLRP10 in Epidermal Homeostasis and Atopic Dermatitis
2026-09-30
The 2024 Cell Death and Disease study identifies NLRP10 as a regulator of epidermal homeostasis, linking keratinocyte survival to p63-dependent differentiation and barrier integrity. Using human skin evidence and an air-lift skin-equivalent model, the authors define a mechanism involving DISC-associated caspase-8 control and p63 stabilization, providing a framework for studying barrier failure in atopic dermatitis.
-
Alfuzosin HCl: Designing Better Urinary Assays
2026-09-29
Alfuzosin HCl research can benefit from a clearer separation between receptor engagement, smooth-muscle function, and clinical urinary outcomes. This article translates endpoint logic from the EAGLE-2 and EAGLE-3 gepotidacin trials into a practical, scientifically bounded framework for Alfuzosin Hydrochloride assay design.
-
Phosbind Acrylamide for Phosphorylation Workflows
2026-09-29
Phosbind Acrylamide converts phosphorylation-dependent migration changes into an antibody-independent SDS-PAGE readout for kinase assays and signaling studies. This workflow also shows how to use the reagent as an orthogonal assay for the LKB1–TGM1/3 axis described in a recent metastasis study, while distinguishing phosphorylation from transamidation.
-
Tiamulin (Thiamutilin): Mechanism and Use
2026-09-28
Tiamulin, also called Thiamutilin, is a pleuromutilin antibiotic for veterinary control of respiratory and enteric infections in pigs and poultry. Its 50S-ribosome binding, species-dependent metabolism, and residue limits define how researchers should interpret antimicrobial, pharmacokinetic, and anti-inflammatory data.
-
Mitochondrial Calcium Signaling Restrains Ferroptosis
2026-09-28
The study links mitochondrial calcium uptake through MCU to acetyl-CoA-dependent GPX4 acetylation, identifying a metabolic route that helps sustain GPX4 activity and suppress ferroptosis. Genetic rescue, mutagenesis, structural analysis, and tumor experiments connect this pathway to organismal survival and cancer growth, while also defining questions for follow-up work.
-
α2-AR Agonism: From Receptor Biology to OS Research
2026-09-27
A translational perspective on α2-adrenergic receptor agonism in osteosarcoma recurrence research, integrating recent immune-microenvironment findings with practical guidance for rigorous preclinical studies.
-
Tamsulosin for Cell Assays: A Practical Research Guide
2026-09-26
This scenario-based guide explains how to use Tamsulosin (SKU C6445) as a biological perturbation in cell viability and receptor-signaling research—not as a viability reagent. It connects assay controls and solvent handling with product formulation details and the limits of clinical evidence.
-
Tolazoline Workflows for Receptor and Islet Studies
2026-09-25
Tolazoline supports controlled dissection of α2-adrenergic receptor signaling, with a separate, concentration-sensitive effect on pancreatic β-cell KATP channels. This practical guide connects airway and islet workflows to a brain-insulin-signaling study without implying that Tolazoline has demonstrated efficacy in Alzheimer’s disease.
-
Alfuzosin HCl for α1 Receptor Research
2026-09-25
Build BPH-focused experiments around Alfuzosin HCl with workflows that connect α1-receptor pharmacology to smooth-muscle function and analytical verification. The article also shows how to borrow rigorous endpoint design from UTI trials without confusing an antibiotic study with evidence for alfuzosin efficacy.
-
Lamotrigine in Epilepsy and Cardiac Assays
2026-09-24
Build interpretable Lamotrigine studies with a practical workflow for sodium-channel assays, epilepsy models, and cardiac electrophysiology. The guide separates product-reported activity from suggested starting conditions and shows how orthogonal readouts can prevent overinterpreting a single assay.
-
Dorsomorphin 2HCl: AMPK Inhibitor Guide
2026-09-24
Dorsomorphin 2HCl is an AMPK inhibitor used to test pathway involvement, but it also inhibits BMP signaling through BMP type I receptors. In a mouse model of alcohol-induced hepatic lipid accumulation, dorsomorphin treatment weakened the benefits associated with Lactiplantibacillus plantarum P101, supporting AMPK involvement without establishing a treatment effect in humans.
-
EV-Transferred ACLY Reprograms Macrophages in HCC
2026-09-23
The study identifies extracellular vesicle (EV)-transferred ATP-citrate lyase (ACLY) as a metabolic signal that helps convert monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its engineered vesicle experiments support a causal role for ACLY and suggest that selectively targeting this pathway may improve checkpoint immunotherapy, while leaving important questions about clinical translation and broader tumor relevance.
-
Epinephrine Bitartrate: Adrenergic Research Guide
2026-09-23
Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for controlled α- and β-receptor activation in cell, cardiovascular, and translational studies. Product specifications and a canine pharmacokinetic study support distinct research-use benchmarks, but canine intranasal exposure does not establish human dose equivalence.
-
CSBTA Pharmacokinetics in MASH Mice
2026-09-22
The reference study integrates pharmacokinetics, tissue distribution, cellular transport, and metabolic-enzyme analysis to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic and hepatic exposure, providing a mechanistic basis for more rational dose design in MASLD/MASH research.
-
α-Bungarotoxin for Nicotinic Receptor Blockade
2026-09-22
Use α-Bungarotoxin as a high-affinity α7 nAChR antagonist to separate receptor-dependent cholinergic effects from downstream toxicity, inflammation, and cell-death signals. This practical workflow connects classical neuroscience experiments with the placental necroptosis model reported in recent research.